Research ArticleArticle
Open Access
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
Ellen M. Ginzler, Daniel J. Wallace, Joan T. Merrill, Richard A. Furie, William Stohl, W. Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Z. John Zhong, William W. Freimuth, Michelle A. Petri the LBSL02/99 Study Group and Michelle A. Petri the LBSL02/99 Study Group
The Journal of Rheumatology November 2013, jrheum.121368; DOI: https://doi.org/10.3899/jrheum.121368
Ellen M. Ginzler
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
Daniel J. Wallace
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
Joan T. Merrill
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
Richard A. Furie
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
William Stohl
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
W. Winn Chatham
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
Arthur Weinstein
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
James D. McKay
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
W. Joseph McCune
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
Z. John Zhong
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
William W. Freimuth
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
Michelle A. Petri
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
Michelle A. Petri
From the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York; Cedars-Sinai Medical Center/David Geffen School of Medicine at the University of California at Los Angeles; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; North Shore-Long Island Jewish Health System, Lake Success, New York; Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California; University of Alabama at Birmingham, Alabama; MedStar Washington Hospital Center, Washington, DC; Oklahoma Center for Arthritis Therapy and Research, Tulsa, Oklahoma; University of Michigan, Ann Arbor, Michigan; Human Genome Sciences Inc., Rockville; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by GlaxoSmithKline, Uxbridge, UK; and Human Genome Sciences Inc., Rockville, Maryland, USA. Drs. Ginzler and Merrill have received consulting fees and research support from GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS). Dr. Wallace has received consulting and speaking fees, and/or honoraria from GSK and HGS. Drs. Furie and Petri have received research or grant support, travel support, and payment for review activities, board membership, and consultancy from GSK and HGS. Dr. Stohl has received clinical trial support from GSK and HGS. Dr. Chatham has received research or grant support and travel support from GSK and HGS. Dr. Weinstein has received research support from HGS, and consulting and speaking fees from GSK and HGS. Dr. McKay has no financial conflicts to report. Dr. McCune has received research support from HGS. Drs. Zhong and Freimuth were employed by and owned stock in HGS. E.M. Ginzler, MD, SUNY Downstate Medical Center; D.J. Wallace, MD, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA; J.T. Merrill, MD, Oklahoma Medical Research Foundation; R.A. Furie, MD, North Shore-Long Island Jewish Health System; W. Stohl, MD, PhD, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine; W.W. Chatham, MD, University of Alabama at Birmingham; A. Weinstein, MD, Georgetown University; J.D. McKay, DO, Oklahoma State University Center for Health Sciences; W.J. McCune, MD, University of Michigan; Z.J. Zhong, PhD; W.W. Freimuth, MD, PhD, Human Genome Sciences Inc.; M.A. Petri, MD, Johns Hopkins University. Address correspondence to Dr. Ginzler, Rheumatology, Department of Medicine, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, New York 11203, USA. E-mail: ELLEN.GINZLER@downstate.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication August 29, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
Ellen M. Ginzler, Daniel J. Wallace, Joan T. Merrill, Richard A. Furie, William Stohl, W. Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Z. John Zhong, William W. Freimuth, Michelle A. Petri the LBSL02/99 Study Group, Michelle A. Petri the LBSL02/99 Study Group
The Journal of Rheumatology Nov 2013, jrheum.121368; DOI: 10.3899/jrheum.121368
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
Ellen M. Ginzler, Daniel J. Wallace, Joan T. Merrill, Richard A. Furie, William Stohl, W. Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Z. John Zhong, William W. Freimuth, Michelle A. Petri the LBSL02/99 Study Group, Michelle A. Petri the LBSL02/99 Study Group
The Journal of Rheumatology Nov 2013, jrheum.121368; DOI: 10.3899/jrheum.121368